Why the study?
Little is known about cardiac troponin elevation after diagnostic invasive intracoronary examination (IVUS or OCT) and its prognostic influence.
Does diagnostic invasive intracoronary examination (IVUS or OCT) increase the risk of periprocedural myocardial injury and subsequent major adverse cardiac events in patients with stable coronary artery disease?
Does diagnostic invasive intracoronary examination (IVUS or OCT) increase the risk of periprocedural myocardial injury and subsequent major adverse cardiac events in patients with stable coronary artery disease?
Diagnostic invasive intracoronary examination with IVUS or OCT causes minor periprocedural myocardial injury in a small percentage of patients, but this is not associated with an increased risk of subsequent major adverse cardiac events.
PMI after diagnostic IVUS/OCT was not associated with MACE; leaves open whether routine monitoring alters outcomes in stable CAD.
Recent studies reported that cardiac troponin elevation after percutaneous coronary intervention is related to adverse cardiac events. Intravascular ultrasound (IVUS) and optical coherence tomography (OCT) are often used to assess lesion characteristics in the coronary arteries. However, little is known about the trend of cardiac troponin elevation after diagnostic invasive intracoronary examination and the prognostic influence. We assessed the relationship between myocardial injury manifested by the high-sensitivity cardiac troponin T (hs-cTnT) level after invasive intracoronary examination and future adverse cardiac outcomes. We evaluated 115 patients with stable coronary artery disease who underwent IVUS or OCT for detailed coronary assessment during coronary angiography (CAG). Baseline and post-procedural (within 24 hours after examination) hs-cTnT were measured. In consequence, post-procedural hs-cTnT level and percentage increase were higher in patients with IVUS or OCT during CAG than in those without. Periprocedural myocardial injury (PMI, defined as post-procedural hs-cTnT with upper reference limit greater than five-fold) occurred in 10 (8.6%) patients. There were no significant differences in baseline characteristics between patients with and without PMI, except for left-ventricular diastolic dimension. Only two major adverse cardiac events (MACE, defined as cardiovascular death, nonfatal myocardial infarction, and target lesion revascularization) occurred in non-PMI during a mean observation period of 32 ± 18 months. On Kaplan-Meier analysis, MACE-free survival rate was similar between PMI and non-PMI. In conclusion, a few imperceptible PMI derived by hs-cTnT assay occurred after diagnostic invasive intracoronary examination. However, it was not associated with subsequent poor cardiac outcome.
No takes yet. Share an insight, caveat, or question.
Sanuki et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: